Page 8 - Financial Code News Today

PARIS and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the pricing of its previously announced global follow-on offering reserved to specified categories of investors, consisting of (i) an offering of 3,106,907 American Depos...

PARIS and CAMBRIDGE, Mass., Nov. 01, 2023 -- NANOBIOTIX , a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer,...

PARIS and CAMBRIDGE, Mass., Nov. 01, 2023 -- NANOBIOTIX , a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer,...

CONTENTS APPENDIX Cross-reference table of the management report of the Board of Directors ...

CONDITIONS DUTILISATION DU FORMULAIRE GENERALITES : Il sagit dun formulaire unique prévu par larticle R. 225-76 du...

Annual Shareholders Meeting 2023 Paris, May 17, 2023 Corporate Video ...

EQS-News: ABIVAX / Key word(s): IPOAbivax announces Closing of its Initial Public Offering on the Nasdaq Global Market 24.10.2023 / 22:05 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax announces Closing of its Initial Public Offering on the Nasdaq Global MarketPARIS, France, Oct...

In an important judgment handed down on 29 June 2023 (Case C-211/22), the Court of Justice of the European Union (the "CJEU") ruled that a vertical agreement to fix minimum prices does...

Abivax Announces Closing of its Initial Public Offering on the Nasdaq ...

PARIS, FRANCE / ACCESSWIRE / October 24, 2023 / Abivax SA (PARIS:FR) (" Abivax " or the " Company "), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's